
Coherus Oncology, Inc.: updates and filings
Price
$0.39
November 19, 2026Market cap $58M
What Ploutos Investor adds for Coherus Oncology
Part of Ploutos Investor, €9.99 a month
- The full history: 14 fiscal years, from 2012
- The estimated fair value, with its range and its certainty
- The full analysis, 18 a month
- More questions to the chat on its filings
- Excel with every year
- An email when it reports, changes its dividend or an officer buys
Sign in with a free account to see the last 5 fiscal years.
Notes on these figures
- The share price has fallen 50% since Nov 9, 2026, when the 10-Q these figures come from was filed ($0.82 then, $0.41 on Nov 18, 2026). The figures date from before that move.10-Q
- The interest the company pays is far more than the debt we can read would cost, so part of its borrowing is missing from the figures. We leave out the debt, net cash, enterprise value and the multiples built on them.
What comes next, and what happened
Its next results and latest dividend, and the filings that told of something: results, deals, people, debt. In plain words, each linked to the filing.
Next results
last Nov 9, 2026next Feb 8, 2027
An estimate from when it has reported before, which has been regular. The company announces the date itself.
November 2026
August 2026
- 28FriOtherOther material eventsDocument
- 17MonOtherRegulation FD disclosure, other material eventsDocument
- 17MonDealMaterial agreement entered, material agreement ended, new material financial obligationDocument
- 5WedReportQuarterly report · for the period to Jun 30, 2026Document
- 5WedResultsResults of operationsDocument
Its SEC filings
What it has filed lately, newest first, linked to the document itself.
- Nov 9, 2026Quarterly reportfor the period to Sep 30, 2026Form10-Q
- Nov 9, 2026Results of operationsForm8-K
- Oct 29, 2026Regulation FD disclosure, other material eventsForm8-K
- Aug 28, 2026Other material eventsForm8-K
- Aug 17, 2026Regulation FD disclosure, other material eventsForm8-K
- Aug 17, 2026Material agreement entered, material agreement ended, new material financial obligationForm8-K
- Aug 5, 2026Shares registered for employeesFormS-8
- Aug 5, 2026Quarterly reportfor the period to Jun 30, 2026Form10-Q
- Aug 5, 2026Results of operationsForm8-K
- Jul 27, 2026Over-5% holder statement (passive)FormSCHEDULE 13G
- Jun 15, 2026Change of auditorForm8-K
- Jun 1, 2026Shareholder voteForm8-K
- May 28, 2026Additional annual meeting materialFormDEFA14A
- May 15, 2026Over-5% holder statement (passive) (amendment)FormSCHEDULE 13G/A
- May 11, 2026Quarterly reportfor the period to Mar 31, 2026Form10-Q
- May 11, 2026Results of operationsForm8-K
- May 11, 2026Over-5% holder statement (passive) (amendment)FormSCHEDULE 13G/A
- May 5, 2026Additional annual meeting materialFormDEFA14A
- Apr 29, 2026Over-5% holder statement (passive) (amendment)FormSCHEDULE 13G/A
- Apr 27, 2026Over-5% holder statement (passive) (amendment)FormSCHEDULE 13G/A
- Apr 20, 2026Annual report to shareholdersfor the period to Dec 31, 2025FormARS
- Apr 20, 2026Annual meeting proxy statementFormDEF 14A
- Apr 14, 2026Additional annual meeting materialFormDEFA14A
- Apr 9, 2026Preliminary proxy statementFormPRE 14A
- Mar 26, 2026Over-5% holder statement (passive) (amendment)FormSCHEDULE 13G/A
| Filed | Form | What it is | Filing |
|---|---|---|---|
| Nov 9, 2026 | 10-Q | Quarterly reportfor the period to Sep 30, 2026 | Document |
| Nov 9, 2026 | 8-K | Results of operations | Document |
| Oct 29, 2026 | 8-K | Regulation FD disclosure, other material events | Document |
| Aug 28, 2026 | 8-K | Other material events | Document |
| Aug 17, 2026 | 8-K | Regulation FD disclosure, other material events | Document |
| Aug 17, 2026 | 8-K | Material agreement entered, material agreement ended, new material financial obligation | Document |
| Aug 5, 2026 | S-8 | Shares registered for employees | Document |
| Aug 5, 2026 | 10-Q | Quarterly reportfor the period to Jun 30, 2026 | Document |
| Aug 5, 2026 | 8-K | Results of operations | Document |
| Jul 27, 2026 | SCHEDULE 13G | Over-5% holder statement (passive) | Document |
| Jun 15, 2026 | 8-K | Change of auditor | Document |
| Jun 1, 2026 | 8-K | Shareholder vote | Document |
| May 28, 2026 | DEFA14A | Additional annual meeting material | Document |
| May 15, 2026 | SCHEDULE 13G/A | Over-5% holder statement (passive) (amendment) | Document |
| May 11, 2026 | 10-Q | Quarterly reportfor the period to Mar 31, 2026 | Document |
| May 11, 2026 | 8-K | Results of operations | Document |
| May 11, 2026 | SCHEDULE 13G/A | Over-5% holder statement (passive) (amendment) | Document |
| May 5, 2026 | DEFA14A | Additional annual meeting material | Document |
| Apr 29, 2026 | SCHEDULE 13G/A | Over-5% holder statement (passive) (amendment) | Document |
| Apr 27, 2026 | SCHEDULE 13G/A | Over-5% holder statement (passive) (amendment) | Document |
| Apr 20, 2026 | ARS | Annual report to shareholdersfor the period to Dec 31, 2025 | Document |
| Apr 20, 2026 | DEF 14A | Annual meeting proxy statement | Document |
| Apr 14, 2026 | DEFA14A | Additional annual meeting material | Document |
| Apr 9, 2026 | PRE 14A | Preliminary proxy statement | Document |
| Mar 26, 2026 | SCHEDULE 13G/A | Over-5% holder statement (passive) (amendment) | Document |
From the company's record at the SEC (EDGAR). The topics of each 8-K are the item codes the company itself filed. Its whole record at the SEC, since Feb 23, 2011.
The full analysis
What do Coherus Oncology's filings show?
The filings are where every one of Coherus Oncology's figures comes from. The full Ploutos AI analysis reads everything the company has filed and shows what stands behind it, with a source for every figure.
- A fair value range built from the filings
- Earnings quality, debt and red flags
- Insider and institutional moves
- The case for and the case against
Related pages
The other pages on US stocks, free to read. On the company pages, the last three fiscal years are open to everyone, five with a free account, and every year with Ploutos Investor.
The figures come from the company's SEC filings and the share price, and describe what it has reported. They are not a score or a fair value.